|
| | Tigilanol tiglate Basic information |
| Product Name: | Tigilanol tiglate | | Synonyms: | Tigilanol tiglate;2-Butenoic acid, 2-methyl-, (1aR,1bR,1cS,2aR,3S,3aS,6aS,6bR,7R,8R,8aS)-1a,1b,1c,2a,3,3a,4,6a,6b,7,8,8a-dodecahydro-3,3a,6b-trihydroxy-2a-(hydroxymethyl)-1,1,5,7-tetramethyl-8a-[(2S)-2-methyl-1-oxobutoxy]-4-oxo-1H-cyclopropa[5',6']benz[1',2':7,8]azuleno[5,6-b]oxiren-8-yl ester, (2E)-;EBC 46;EBC46;EBC-46;(1cS,2aR,3S,3aS,6bR,7R,8R,8aS)-3,3a,6b-trihydroxy-2a-(hydroxymethyl)-1,1,5,7-tetramethyl-8a-((2-methylbutanoyl)oxy)-4-oxo-1a | | CAS: | 943001-56-7 | | MF: | C30H42O10 | | MW: | 562.65 | | EINECS: | | | Product Categories: | | | Mol File: | 943001-56-7.mol |  |
| | Tigilanol tiglate Chemical Properties |
| Boiling point | 682.1±55.0 °C(Predicted) | | density | 1.35±0.1 g/cm3(Predicted) | | pka | 10?+-.0.70(Predicted) | | InChIKey | YLQZMOUMDYVSQR-FOWZUWBHSA-N | | SMILES | C(O[C@H]1[C@@]2(OC(=O)[C@@H](C)CC)C(C)(C)[C@@]2([H])[C@]2([H])[C@]3([H])O[C@]3(CO)[C@@H](O)[C@@]3(O)[C@@]([H])(C=C(C)C3=O)[C@@]2(O)[C@@H]1C)(=O)/C(/C)=C/C |
| | Tigilanol tiglate Usage And Synthesis |
| Uses | Tigilanol tiglate is a medication used to treat dogs with non-metastatic, skin-based (cutaneous) mast cell tumors (MCTs). | | Definition | ChEBI: Tigilanol tiglate is a diterpenoid natural product isolated from the kernels of the Australian blushwood tree (Fontainea picrosperma). It is approved as a veterinary pharmaceutical for the treatment of non-metastatic and non-resectable canine mast cell tumours. It has a role as an antineoplastic agent, a plant metabolite and a protein kinase C agonist. It is a diterpenoid, a phorbol ester, a diester and an organic heteropentacyclic compound. | | Mechanism of action | The active substance in Tigilanol tiglate stimulates the action of enzymes called protein kinase C which are involved in regulating processes that can help cells grow and survive. By activating these enzymes blood supply to cells gets interrupted, resulting in the death of the cell. By injecting Stelfonta into the tumour, cancer cells will be affected, so destroying the tumour, and leaving a wound at the injection site. |
| | Tigilanol tiglate Preparation Products And Raw materials |
|
